tirzepatide and cardiovascular outcomes Real-World of Obesity Treatment With Versus Semaglutide in Non-Diabetic Adults In obese individuals without diabetes, tirzepatide was associated with a lower risk of cardiovascular events, especially incident HF Tirzepatide vs Dulaglutide for Cardiovascular

Stung by high prices, Americans make their own weight-loss drugs By Robin Respaut and Maggie Fick SAN FRANCISCO (Reuters) -In what she calls the "wild west" of obesity medicines, Missouri-based Amy Spencer is a pioneer

Almost half of patients taking the top dose lost at least 30 percent of their body weight results normally only seen with weight-loss surgery

However there are challenges, with some participants observing increased gastrointestinal adverse events

This can create a cycle where side effects lead to missed doses, which then cause worse side effects upon resumption

The genetics arent enough, however

Many patients successfully manage fatigue through minor modifications while continuing effective treatment